Registration & housing are now open for ASTRO's 2026 Annual Meeting:
Join us in Boston from September 26 - 30 for ASTRO's 68th Annual Meeting, with the theme "Data to Dialogue: Communicating Radiotherapy's Value to Advance Care".
Experience a complete program with engaging education sessions, cutting-edge science, the latest cancer research, and countless networking opportunities. You won't want to miss the event of the year for the #radonc community! #ASTRO26
Register now: https://t.co/0cfJEozWBY
Happening TOMORROW - LIVE webinar:
“Common Misinformation About Prostate Cancer and What To Do”
June 8 | 1:00 p.m. ET
Moderated by ASTRO President Neha Vapiwala, MD, FASTRO, with speaker Stacy Loeb, MD, MSc, PhD (Hon). FREE for ASTRO members.
Register today: https://t.co/h6QCdmD6G8
@NehaVapiwala@LoebStacy
🎙️NEW episode of Rad Onc Report:
"A CEO's Perspective on AI in Radiation Oncology"
In this episode, continuing the series on AI in Radiation Oncology, Eva Katsoulakis, MD, a member of ASTRO’s AI Resource Panel, speaks with Kurt Sysock, CEO and co-founder of Radformation.
Watch this clip & listen now on:
ASTRO's website: https://t.co/94vx1CIcQx
Spotify: https://t.co/JWD0vPK52r
Apple Podcasts: https://t.co/fYZPOXHzYu
@EvaKatsoulakis@ksysock@Radformation
Get to know our ASTRO 2026 Keynote Speaker: Scott Gottlieb, MD
Dr. Gottlieb served as the 23rd FDA Commissioner. He is currently a senior fellow at the American Enterprise Institute and partner at New Enterprise Associates.
We invite you to hear directly from him at the ASTRO Annual Meeting from September 26-30.
Learn more & register to join us at #ASTRO26: https://t.co/acpQqc9dEe
@ScottGottliebMD
Apply now for the ASTRO Radiation Oncology Resident Fellowship:
Proposals due Monday, June 29
The 2026 ASTRO Resident Fellowship program provides a radiation oncology resident (PGY-3 or later) with funding for a mentored research project and a one-year, remote assignment working part-time with AstraZeneca colleagues.
This program is supported by an educational grant from AstraZeneca.
Learn more & apply: https://t.co/CxIYs5QwBY
@AstraZeneca@ARRO_org@ASTRO_org
The 2026 Multidisciplinary Head & Neck Cancers Symposium is available onDemand through the ASTRO Academy!
Explore 18+ hours of in-depth head & neck education & earn up to 18.00 AMA PRA Category 1 Credits™. Plus, get two years of onDemand access to revisit any session, anytime.
Available now: https://t.co/6pzmkqiYk2
@AHNSinfo@ASCO@sitcancer@hncalliance@oralcancerfnd@spohnc_1
🌎Are you a #RadOnc Resident interested in Global Health?
Apply to the ASTRO/ARRO Global Health Scholars Program!
Applications for 2026 are open now through June 14, 2026. This program supports radiation oncology residents in bringing their passion for global health to life.
Learn more & apply today: https://t.co/PxshEyzG9m
@ARRO_org
Proud to join an outstanding international faculty for the first-ever ASTRO Global Refresher kicking off today in Cairo,Egypt! 🇪🇬🌍A major milestone in @ASTRO_org’s global education efforts, bringing together experts committed to advancing radiation oncology&cancer care worldwide
Get to know our ASTRO 2026 Keynote Speaker: Ezekiel Emanuel, MD, PhD
Dr. Emanuel is an oncologist, the most widely cited bioethicist in history, and an architect of the ACA. He serves as Vice Provost for Global Initiatives at the University of Pennsylvania and is a world leader in health policy and bioethics.
We invite you to hear directly from him at the ASTRO Annual Meeting from September 26-30.
Learn more & register to join us at #ASTRO26: https://t.co/XAbn9QNJoO
@ZekeEmanuel
📍 Join us in Boston or virtually for ASTRO 2026, September 26–30!
Registration and housing are now open: book early for the best hotel rates and selection.
⏰Register by June 25, 2026, to save with Early-bird rates. We can’t wait to see you at ASTRO’s 68th Annual Meeting! #ASTRO26
Secure your spot today: https://t.co/c0yQOrBccR
📢 New in this week's ASTROgram:
⭐ ASTRO 2026: Get to know keynote presenters Ezekiel Emanuel, MD, PhD, and Scott Gottlieb, MD
⭐ June 8 Webinar: Misinformation about Prostate Cancer
⭐ New Rad Onc Report: AI in RO with Kurt Sysock, CEO of Radformation
⭐ New On Target Podcast: Preparing patients for prostate cancer radiation treatment
⭐ ASTRO comments on the PROTEUS clinical trial
🔗 https://t.co/VjiRHf7MES
Check out Mentor Connect: ASTRO’s new and improved mentoring platform!
From students to seasoned pros - connect, grow and thrive with smarter matching and a year-round space built for mentorship.
Join today to share your expertise & support the next generation, receive guidance & actionable career advice and build lasting connections within the radiation oncology community.
Learn more & sign up today: https://t.co/UgSmmHvCUI
The #PROTEUS trial contributes important knowledge to the evolving evidence on high-risk #prostatecancer treatment options. ASTRO’s new summary document from @NehaVapiwala and @AmarUKishan is a member resource for discussions with your #multidisciplinary colleagues and patients.
https://t.co/HywTq0w7oa
🎙️NEW "On Target" episode:
What to Expect During Prostate Cancer Radiation Treatment: Part 2
In part two of this prostate cancer series, Dr. Christian Okoye and Dr. Anesa Ahamad explain what patients can expect once radiation treatment begins.
🎧Listen now on
ASTRO's website: https://t.co/dqwsIhiQ8K
Spotify: https://t.co/kJKn3ruysC
Apple Podcasts: https://t.co/rnAnMpeNI9
@DocAnesa
Congratulations to
- NYOH Albany Cancer Center, Albany, New York
- NYOH Amsterdam Cancer Center, Amsterdam, New York
- NYOH Clifton Park Cancer Center, Clifton Park, New York
for achieving reaccreditation through ASTRO’s APEx - Accreditation Program for Excellence®. 🎉
➡️Learn more & join the list of accredited facilities: https://t.co/nGPDFq5w3u
@NYOHPC
📌 Impact of Radionecrosis and Local Recurrence on Overall Survival After Stereotactic Radiosurgery for Brain Metastases 🧠
🔗 https://t.co/zLFWzoaKKY
@ASTRO_org@EJVaios@PeterFecci@MuzamilArshad18
🔹1383 pts
🔸 large, multi-institutional cohort
🔹 Patients diagnosed with LR were diagnosed sooner after SRS than RN (5.8 vs 8.3 months)
🔸 Local recurrence was associated with significantly worse OS than radionecrosis (15.2 vs 40.4 months)
🔹 Patients symptomatic from either LR or RN presented earlier after SRS than asymptomatic patients and had worse OS
🔸 On binomial logistic regression, RN was associated with single fraction SRS (odds ratio [OR] = 0.38, P = 0.012), receipt of immunotherapy after SRS (OR = 0.32, P < 0.014), and a longer interval from SRS (OR = 0.94, P = 0.028).
FREE for ASTRO members-in-training!
New LIVE Webinar: eContouring for Breast Cancer
June 25, at 12:00 p.m. ET | Led by Bethany Anderson, MD, this webinar offers hands-on contouring practice on real cases, plus a live Q&A session.
ASTRO members receive a discount and members-in-training can register for free thanks to support from Speed of Light – The ASTRO Foundation’s Juan A. del Regato Fund.
Register now: https://t.co/Q6HkueKkj1
@SpeedofLightFdn@ARRO_org@RadOncMom
Congratulations to South Carolina Oncology Associates for achieving reaccreditation through ASTRO’s APEx - Accreditation Program for Excellence®. 🎉
➡️Learn more & join the list of accredited facilities: https://t.co/0X7jSlNwn3
@sconcology
Call for nominations: 2026 Publication Excellence Awards!
ASTRO is celebrating early career investigators leading the way in radiation oncology. Nominate yourself or a colleague for the 2026 Speed of Light Publication Excellence Awards or the ARRO Health Care Access Publication Award.
Learn more & apply today: https://t.co/LykGXIc5Ix
@ARRO_org
Congratulations to VA North Texas Health Care System for achieving reaccreditation through ASTRO’s APEx - Accreditation Program for Excellence®. 🎉
➡️Learn more & join the list of accredited facilities: https://t.co/p42au9mwNn
@VANorthTexas